Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Vomiting 39Nausea 31Neoplasms 10Breast Neoplasms 10Lymphoma 9Multiple Myeloma 7Ovarian Neoplasms 6Lymphoma, Non-Hodgkin 6Leukemia, Myeloid, Acute 6Sezary Syndrome 4Myeloproliferative Disorders 4Leukemia 4Carcinoma, Non-Small-Cell Lung 4Pruritus 3Primary Myelofibrosis 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pdgfra-Associated Chronic Eosinophilic Leukemia 3Neoplasms, Plasma Cell 3Myelodysplastic Syndromes 3Mycosis Fungoides 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Neutrophilic, Chronic 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3

Interventions

Oxaliplatin 271Fluorouracil 268Capecitabine 235Leucovorin 209Irinotecan 152Radiotherapy 139Bevacizumab 114Cetuximab 82Surgical Procedures, Operative 51Folfox protocol 49Neoadjuvant Therapy 45Drug Therapy 43Radiation 42Chemotherapy, Adjuvant 34Chemoradiotherapy 34Panitumumab 27Magnetic Resonance Spectroscopy 26XELOX 25Radiotherapy, Intensity-Modulated 23Biopsy 20Surveys and Questionnaires 18Laparoscopy 18Proctectomy 17Floxuridine 17Early Intervention, Educational 16Nivolumab 15Immunohistochemistry 15Gene Expression Profiling 15Gemcitabine 15pembrolizumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rectal Neoplasms × Aprepitant × Clear all
NCT00381862 2017-06-12

Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX

OHSU Knight Cancer Institute

Phase 2 Completed
54 enrolled 7 charts
Gastrointestinal

Colonic Neoplasms, Nausea, Rectal Neoplasms, Vomiting, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡